Alipay’s Xiang Hu Bao Online Mutual Aid Platform Attracts 100 Million Participants in One Year
Xiang Hu Bao, an online mutual aid platform introduced by Alipay, has attracted over 100 million participants since it was launched just over a year ago, helping health protection in China become more inclusive by making it more accessible especially for the lower income and those living in rural areas.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191126005952/en/
100 million participants signed up for Xiang Hu Bao in one year. (Graphic: Business Wire)
As of November 22, 2019, more than 10,000 people have received financial aid for their medical needs through Xiang Hu Bao, contributed by other participants in the platform. More than two thirds of Xiang Hu Bao participants earn below RMB 100,000 (US$ 14,000) per year, while a third of them come from rural China.
Xiang Hu Bao, which literally means “mutual protection”, was launched in October 2018 and provides its participants with a basic health plan against 100 types of critical illness, including thyroid cancer, breast cancer, lung cancer, critical brain injury and acute myocardial infarction. All participants share the risk of becoming critically ill and bear the related medical expenses as a collective. While Xiang Hu Bao is not a health insurance product, it complements premium health insurance offerings in the market that have wider range and depth of coverage.
“Xiang Hu Bao was designed with inclusiveness in mind,” said Ming Yin, Vice President of Ant Financial. “We hope Xiang Hu Bao can support participants to help one another by providing a trustworthy platform in addition to the medical care protection provided by China’s social security and premium health insurance companies.”
Unlike traditional online mutual aid platforms in China, Xiang Hu Bao is more inclusive because it requires no upfront payment or admission fees. It is available to participants between 30 days and 59 years of age who meet basic health and risk criteria. When a participant makes a claim, supporting evidence must be submitted via the Alipay app and then it goes through a review and approval process. Traditionally, online mutual aid platforms in China lacked cost-effective capabilities to reduce the risk of fraud, impacting their reputation and therefore prevented them from scaling up to help those people truly in need.
On the Xiang Hu Bao platform, the entire evidence submission process is powered by Alipay’s proprietary consortium blockchain technology, which ensures the process is tamper-proof. Once claims are approved, the participant will receive a one-time payout of up to RMB 300,000 (~US$43,000), the cost of which is shared equally by the other participants. Disputed claims are escalated to an online review board that consists of qualified volunteer participants.
According to Xiang Hu Bao, around six out of ten of its participants come from third and lower tier cities, counties and rural areas. A recent survey conducted by Health Economics and Medical Security Research Center, Nankai University1 examined the annual income of Xiang Hu Bao participants and discovered that two thirds of them earn less than RMB 100,000 (~US$ 14,000). Not surprisingly, around 86% of participants cannot afford medical expenses exceeding RMB 300,000 (~US$ 43,000). Also, the survey shows that 10 percent of Xiang Hu Bao’s participants had no other health plans other than Xiang Hu Bao.
“The majority of Xiang Hu Bao’s participants are from middle or low-income communities who are at great risk of falling into poverty if they become critically ill,” said Zhu Minglai, director at the Health Economics and Medical Security Research Center, Nankai University, adding that Xiang Hu Bao has enabled low-income communities to receive basic health protection at an affordable cost and supplements other health plans provided by the public and private sectors in China.
In addition to creating value for its participants, Xiang Hu Bao also helps cultivate a greater understanding of the benefits for obtaining protection against illnesses. According to an FT Confidential Research survey,2 one in three of Xiang Hu Bao’s participants intend to buy a critical illness insurance product over the next six months, while for those who do not participate in the platform, the intention of purchasing is only 22 percent. Furthermore, sales of health policies offered by partner insurance companies on the Ant Insurance Platform have increased by over 60% as of June 2019, in comparison to October 2018 when Xiang Hu Bao was launched.
About Alipay
Operated by Ant Financial Services Group, Alipay is the world’s leading payment and lifestyle platform. Launched in 2004, Alipay serves over 1.2 billion users with its local e-wallets partners as of June 2019. Over the years, Alipay has evolved from a digital wallet to a lifestyle enabler. Users can hail a taxi, book a hotel, buy movie tickets, pay utility bills, make appointments with doctors, or purchase wealth management products directly from within the app. In addition to online payments, Alipay is expanding to in-store offline payments both inside and outside of China. Alipay’s in-store payment service covers over 50 markets across the world, and tax reimbursement via Alipay is supported in 35 markets. Alipay currently supports 27 currencies, and works with over 250 overseas financial institutions and payment solution providers to enable cross-border payments for Chinese travelling overseas and overseas customers who purchase products from Chinese e-commerce sites.
1 Source: https://mp.weixin.qq.com/s/HjRYY9jsbpe2LWhabI0ijw (in Chinese)
2 Source: https://www.ft.com/content/3bbf683e-a325-11e9-974c-ad1c6ab5efd1
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191126005952/en/
Contact information
Alipay / Xiang Hu Bao
Le SHEN
E: shenle.sl@antfin.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Thredd Powers Successful Migration of BigPay’s Card Portfolio to Next-Gen Platform26.11.2025 10:00:00 EET | Press release
Thredd, the leading next-generation global payments processor, has successfully migrated BigPay’s virtual and physical card portfolio from its previous, legacy processor to Thredd’s next-generation platform, underscoring Thredd’s leadership in complex card portfolio migrations. The migration project, one of several in recent years, included over 2.5 million cards and highlights Thredd’s unique combination of deep migration experience, robust processes, and advanced technology—qualities increasingly critical as the industry faces a wave of modernisation and replatforming. This achievement comes at a pivotal moment for the industry. Industry analysts estimate that retail banks failing to modernise could see 10% to 15% of their payments revenue at risk annually as legacy platforms struggle to keep pace with demands for hyperpersonalization, digital experiences, faster time-to-market, and operational efficiencies. With more than 100 million cards per year expected to move to modern platfor
With Two in Five Employees Undergoing Fertility Treatment Leaving Their Jobs or Considering Quitting, Are Companies Doing Enough?26.11.2025 09:00:00 EET | Press release
An international survey, spanning Australia, France, Japan, Poland and the UK, has found that many employees experiencing fertility challenges lack support in the workplace, with almost two in five (39%) leaving or considering leaving their roles while undergoing treatment.1 ‘The Impact of Fertility Challenges at Work: International Insights’ survey by Ferring Pharmaceuticals, Fertility Matters at Work and This Can Happen shows that, despite growing awareness of reproductive health, two thirds (67%) who have experienced fertility challenges say that their workplaces do not offer support for employees undergoing fertility treatment, with France the least likely to provide it (88%).1 60% said they were not clearly entitled to time off for fertility appointments, with time recorded as paid leave, unpaid leave or annual leave (26%), and some also reported taking sick leave due to a lack of flexibility (17%).1 With assisted reproduction therapy, including IVF, already accounting for up to 1
Venture Global and Tokyo Gas Announce 20-Year LNG Sales and Purchase Agreement26.11.2025 02:00:00 EET | Press release
Today, Venture Global, Inc. (NYSE: VG) and Tokyo Gas Co., Ltd announced the execution of a new, long-term liquefied natural gas (LNG) Sales and Purchase Agreement (SPA). Under the SPA, Tokyo Gas will procure 1 million tonnes per annum (MTPA) of LNG from Venture Global for 20 years, starting in 2030. This deal marks 7.75MTPA of SPAs signed by Venture Global in the last six months. “With nearly 8 MTPA of new long-term commitments signed this year, Venture Global is pleased to build on our commercial momentum through this new partnership with Tokyo Gas,” said Venture Global CEO Mike Sabel. “Tokyo Gas is a pioneer in the LNG industry and leading provider of natural gas to Japan, and we look forward to working with them as we grow our position as a top LNG supplier to Japan. This agreement will contribute significantly to the US-Japan balance of trade over the duration of the SPA, providing Japan with affordable, reliable American LNG.” About Venture Global Venture Global is an American pro
Airship Study: No-Code Native App Experiences Double Purchase Frequency (+140%), Offering Path to Profitable Holiday Growth26.11.2025 01:08:00 EET | Press release
Mobile-first customer experience company Airship today released new aggregate data analysis findings showing that no-code native app experiences significantly increase conversion for key lifecycle events and more than double purchase frequency. The Airship "Experience Impact” research, which studied over 1,000 in-app retail experiences and 1.7 billion device sessions, quantifies the impact of optimizing end-to-end customer journeys—not just sending messages—using no-code and AI-powered tools to drive loyalty and retention at scale, leading to sustainable profitability in a volatile economic environment. Key Findings Customers exposed to high-impact no-code native app experiences such as optimized onboarding flows, dynamic surveys, or embedded personalized offers, purchase 140% more frequently than app customers who don’t receive them. These experiences, which product owners and marketers can create and adapt without developer resources, significantly increase conversion for key lifecyc
Court Finds That Two Advanced Cell Diagnostics Patents Are Not Infringed by Molecular Instruments’ Proprietary HCR™ RNA-ISH Technology25.11.2025 18:30:00 EET | Press release
Molecular Instruments, Inc. announced today that the Unified Patent Court (UPC) of the European Union has found that Molecular Instruments’ HCR™ RNA-ISH technology does not infringe two patents owned by Advanced Cell Diagnostics, Inc. (a Bio-Techne group company). In a 2024 lawsuit filed in the UPC (proceedings no. UPC CFI 187/2024), Advanced Cell Diagnostics alleged that Molecular Instruments’ HCR™ RNA-ISH technology infringes European patents (EP) 2,500,439 and 1,910,572. The Court in its judgment of 18 November 2025 has rejected that claim and dismissed all of Advanced Cell Diagnostics' lawsuit, ruling that the patents are not infringed either literally or by equivalence (UPC Judgment). This 2025 UPC judgment follows on the heels of an April 2024 UK judgment in which the High Court of England and Wales had already dismissed an earlier infringement lawsuit by revoking the UK parts of the same two Advanced Cell Diagnostics patents (proceedings no. HP-2022-000026), ruling that they wer
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
